Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Lactosucrose (4g-β-d-galactosylsucrose) is a synthetic trisaccharide oligosaccharide composed of galactose, glucose, and fructose. It is indigestible in humans and functions as a prebiotic, being selectively utilized by intestinal Bifidobacterium species. Key effects include the modulation of gut microbiota (increasing Bifidobacterium abundance), potential improvement of body weight in underweight populations (notably in schizophrenia inpatients), enhancement of self-efficacy in depressive patients, and improvement of intestinal calcium absorption. It is not metabolized by human digestive enzymes but fermented by gut bacteria to beneficial short-chain fatty acids. Primary indication is as a prebiotic dietary supplement for modulating gut microbiota and supporting gastrointestinal and metabolic health[1][3][5][7][9].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on lactosucrose.